key: cord-0760291-bc0bed2n authors: Augusto Martins Pereira, Miguel; Marina Mendes da Costa, Lygia; Brito Nascimento, Suelen; Chung Kang, Hye; Henrique Daumas Gabriel, Adelmo title: Hemophagocytic lymphohistiocytosis in adults: A key issue in the COVID-19 era date: 2021-09-17 journal: Clin Infect Pract DOI: 10.1016/j.clinpr.2021.100100 sha: 3444a421c5d45f176d7420032dffb5dedc7f1320 doc_id: 760291 cord_uid: bc0bed2n Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by persistent activation of the mononuclear phagocytic system, systemic inflammation, and hypercytokinaemia, which can lead to liver failure, “sepsis-like syndrome” and ultimately, to multiple organ failure and death. These disorders can be divided into primary and secondary (or reactive), the first, also known as familial HLH, is a genetic condition of childhood, which affects the function of TCD8 and NK cells, and usually presents in the first year of life. The secondary HLH affects mainly adults and adolescents and, it's more related to dysregulation of the immune system. In face of the COVID-19 pandemic and several reports of HLH by SARS-CoV-2, it is necessary to discuss the pathophysiology of HLH in adults more clearly. Thus, we present, for the first time, a didactic approach using illustrations and tables, compiling the most recent and relevant information to better understand this entity. inflammation, and hypercytokinaemia, which can lead to liver failure, "sepsis-like syndrome" and ultimately, to multiple organ failure and death. These disorders can be divided into primary and secondary (or reactive), the first, also known as familial HLH, is a genetic condition of childhood, which affects the function of TCD8 and NK cells, and usually presents in the first year of life. The secondary HLH affects mainly adults and adolescents and, it's more related to dysregulation of the immune system. In face of the COVID-19 pandemic and several reports of HLH by SARS-CoV-2, it is necessary to discuss the pathophysiology of HLH in adults more clearly. Thus, we present, for the first time, a didactic approach using illustrations and tables, compiling the most recent and relevant information to better understand this entity. Keywords: Hemophagocytosis; SARS-CoV-2; COVID-19; haemophagocytic syndrome; mutations  Several cases of HLH in patients infected with SARS-CoV-2 began to be reported.  Inherited variations in genes already associated with primary HLH were identified in adult patients with HLH, so it may play a still unclear role in secondary HLH.  The so-called "cytokine storm" is related to the development of the main clinical and laboratory characteristics of HLH, but it is not exclusive to this condition. Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by persistent activation of the mononuclear phagocytic system, systemic inflammation, and hypercytokinaemia, which can lead to liver failure, "sepsis-like syndrome" and ultimately, to multiple organ failure and death. These disorders can be divided into primary and secondary (or reactive), the first, also known as familial HLH, is a genetic condition of childhood, which affects the function of TCD8 and NK cells. The secondary HLH affects mainly adults and adolescents and, it's more related to dysregulation of the immune system. In face of the The hemophagocytic lymphohistiocytosis (HLH) along with other hyperinflammatory and hyperferritinemic syndromes are in great prominence in the face of the COVID-19 pandemic by the SARS-CoV-2, a virus associated with concepts such as "cytokine storm", hyperinflammatory state, and HLH itself like the SARS-CoV, MERS-CoV. [1] [2] [3] However, despite the clear evidence of hyperinflammation, some do not meet diagnostic criteria for sHLH indicating that in those cases a still not well-defined hyperinflammatory syndrome may be the cause. Authors believe it could be an associated innate neutrophilic hyperinflammatory response or virus-associated-cytokine release syndrome, a condition referred to only as COVID-Cytokine Storm Syndrome or other possible differential diagnoses. In 2014, it was validated a score of 9 variables, the HScore, to estimate the risk of an individual having HLH. In 2020, given the COVID-19 pandemic and the identification of a subgroup of patients with sHLH, a condition with high mortality, a Lancet recommendation proposed screen patients with severe COVID-19, using the HScore system to guide the immunomodulating/ immunosuppressive therapies. [4] However, the use of this system has been the subject of controversy regarding its sensitivity, given the clinical and laboratory peculiarities of these patients. [4] The current view of HLH is an inability to adequately restrict the stimulating effects of various immunological triggers, presenting as primary or familial HLH (pHLH) and reactive or secondary (HLH). It is a common terminal pathway, but with different "roots". [5] Defects in granule-mediated cytotoxicity in the innate (NK cells) and adaptive (TCD8 cells) immune system, whether in signaling, traffic, exocytosis, or perforin formation [6] appear to be the common underlying mechanism. Inherited variations in genes already associated with pHLH may play a still unclear role in HLH in adults. [7] [8] In other words, the hypothesis is that changes in the cytotoxic function due to hypomorphic missense and splice-site mutations decrease the "immune threshold" so that HLH can be triggered by infections or other immune stimuli. This suggests that the adult form may be a truly polygenic condition. The Fas-dependent apoptosis mechanisms are also implied in the pathophysiology. After stimulation by specific T cells, dendritic cells (DC) are susceptible to death by the activated T cells themselves, by mechanisms dependent on perforin and Fas. It has been shown to limit the accumulation of this cell type, to prevent autoimmunity and systemic inflammation. [9] In experimental studies, the perforin deficiency, together with the deletion of accumulation, uncontrolled T cell activation, and production of INF-γ, especially by TCD8. Thus, the absence of synergism between perforin and the Fas pathway in maintaining DC homeostasis and prevent the onset of a disordered inflammatory cascade would be an important mechanism in the pathophysiology of HLH. [9] In HLH, the increased antigen presentation, their persistence -due to the [6, 9] Tables and figures Figure 1 . Pathophysiology of HLH. Certain triggers (infections, autoimmune diseases, malignancies, among others), induce an inflammatory cascade, leading to the stimulation of NK cells and TCD8 lymphocytes, whose impaired function, whether by monogenic (hereditary) defects already well characterized in pHLH, or by heterozygous mutations in loci that control granule-mediated cytotoxicity, still little explored especially in sHLH difficult the elimination of the antigen or target-cell. The persistence of the antigen prolongs the already dysfunctional inflammatory response and the sustained action of macrophages and lymphocytes. Thus, an environment of hyperkitokinaemia and hyperactivity is created. Hypercytokinaemia is mainly responsible for fever and cytopenias, while the lymphohistiocytic infiltrate is responsible for splenomegaly and of course has a certain contribution to cytopenias. Hereditary haemochromatosis, haemophagocytic lymphohistiocytosis and COVID-19 The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment Secondary HLH is uncommon in severe COVID-19 Treatment of hemophagocytic lymphohistiocytosis in adults When T cells and macrophages do not talk: the hemophagocytic syndromes Hemophagocytic syndrome: primary forms and predisposing conditions Targeted Gene Sequencing of Adult Patients with Hemophagocytic Lymphohistiocytosis Critical role for perforin and Fas-dependent killing of dendritic cells in the control of inflammation Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice None. This study had no funding resources. Not Applicable. The authors declare that they have no conflict or competing interests.